Real-world outcomes and factors impacting treatment choice in relapsed and/or refractory multiple myeloma (RRMM): a comparison of VRd, KRd, and IRd-Reference-Cited by-同舟云学术

Real-world outcomes and factors impacting treatment choice in relapsed and/or refractory multiple myeloma (RRMM): a comparison of VRd, KRd, and IRd

Published:2020-03-09 Issue:4 Volume:13 Page:421-433
ISSN:1747-4086
Container-title:Expert Review of Hematology
language:en
Short-container-title:Expert Review of Hematology

Author:

Chari Ajai¹^ORCID,Richardson Paul G.²,Romanus Dorothy³,Dimopoulos Meletios A.⁴^ORCID,Sonneveld Pieter⁵^ORCID,Terpos Evangelos⁴^ORCID,Hajek Roman⁶,Raju Aditya⁷,Palumbo Antonio³,Cain Lauren E.³,Blazer Marlo⁷,Huang Hui³,Farrelly Eileen⁷,Ailawadhi Sikander⁸

Affiliation:

1. Department of Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai, New York, NY, USA

2. Jerome Lipper Myeloma Center, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA

3. Global Outcomes Research, Millennium Pharmaceuticals, Inc., A Wholly Owned Subsidiary of Takeda Pharmaceutical Company Limited, Cambridge, MA, USA

4. Hematology & Medical Oncology, Department of Clinical Therapeutics, National and Kapodistrian University of Athens, Athens, Greece

5. Department of Hematology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands

6. University Hospital Ostrava and Faculty of Medicine, University of Ostrava, Ostrava, Czech Republic

7. Scientific Consulting, Xcenda, Palm Harbor, FL, USA

8. Division of Hematology/Oncology, Department of Medicine, Mayo Clinic, Jacksonville, FL, United States

Publisher

Informa UK Limited

Subject

Hematology

Link

https://www.tandfonline.com/doi/pdf/10.1080/17474086.2020.1729734

Reference35 articles.

1. Multiple myeloma: routes to diagnosis, clinical characteristics and survival - findings from a UK population-based study

2. Survival of multiple myeloma patients in the era of novel therapies confirms the improvement in patients younger than 75 years: a population-based analysis

3. Prediction of patients with multiple myeloma eligible for second- or third-line treatment in France

4. Use of autologous hematopoietic cell transplantation as initial therapy in multiple myeloma and the impact of socio-geo-demographic factors in the era of novel agents

5. Improved survival in multiple myeloma and the impact of novel therapies

Cited by 32 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Development and validation of algorithms for identifying lines of therapy in multiple myeloma using real-world data;Future Oncology;2024-01-17

2. INSURE: a pooled analysis of ixazomib-lenalidomide-dexamethasone for relapsed/refractory myeloma in routine practice;Future Oncology;2024-01-10

3. Does the Simultaneous Introduction of Several Pharmaceuticals in the Post-Lenalidomide Era Translate to Better Outcomes in Relapse Refractory Multiple Myeloma? Findings from the Real-World Innovation in Multiple Myeloma (REAL IMM) Study;Cancers;2023-12-14

4. Comparison of health care costs and resource utilization for commonly used proteasome inhibitor–immunomodulatory drug-based triplet regimens for the management of patients with relapsed/refractory multiple myeloma in the United States;Journal of Managed Care & Specialty Pharmacy;2023-11

5. A prospective, multicenter, observational study of ixazomib plus lenalidomide-dexamethasone in patients with relapsed/refractory multiple myeloma in Japan;Annals of Hematology;2023-09-11